Advanced search
1 file | 1.28 MB Add to list

Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma

(2017) MOLECULAR CANCER THERAPEUTICS. 16(12). p.2828-2839
Author
Organization
Keywords
Y-90 IBRITUMOMAB TIUXETAN, B-CELL LYMPHOMA, PHASE-II TRIAL, FOLLICULAR LYMPHOMA, LOW-GRADE, MONOCLONAL-ANTIBODY, ANTI-HER2 NANOBODY, CHOP CHEMOTHERAPY, FOLLOW-UP, RITUXIMAB

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • binary/octet-stream
    • |
    • 1.28 MB

Citation

Please use this url to cite or link to this publication:

MLA
Krasniqi, Ahmet, et al. “Theranostic Radiolabeled Anti-CD20 SdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.” MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 12, 2017, pp. 2828–39, doi:10.1158/1535-7163.mct-17-0554.
APA
Krasniqi, A., D’Huyvetter, M., Xavier, C., Van der Jeught, K., Muyldermans, S., Van Der Heyden, J., … Devoogdt, N. (2017). Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. MOLECULAR CANCER THERAPEUTICS, 16(12), 2828–2839. https://doi.org/10.1158/1535-7163.mct-17-0554
Chicago author-date
Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, Kevin Van der Jeught, Serge Muyldermans, José Van Der Heyden, Tony Lahoutte, Jan Tavernier, and Nick Devoogdt. 2017. “Theranostic Radiolabeled Anti-CD20 SdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.” MOLECULAR CANCER THERAPEUTICS 16 (12): 2828–39. https://doi.org/10.1158/1535-7163.mct-17-0554.
Chicago author-date (all authors)
Krasniqi, Ahmet, Matthias D’Huyvetter, Catarina Xavier, Kevin Van der Jeught, Serge Muyldermans, José Van Der Heyden, Tony Lahoutte, Jan Tavernier, and Nick Devoogdt. 2017. “Theranostic Radiolabeled Anti-CD20 SdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.” MOLECULAR CANCER THERAPEUTICS 16 (12): 2828–2839. doi:10.1158/1535-7163.mct-17-0554.
Vancouver
1.
Krasniqi A, D’Huyvetter M, Xavier C, Van der Jeught K, Muyldermans S, Van Der Heyden J, et al. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. MOLECULAR CANCER THERAPEUTICS. 2017;16(12):2828–39.
IEEE
[1]
A. Krasniqi et al., “Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma,” MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 12, pp. 2828–2839, 2017.
@article{8554379,
  author       = {{Krasniqi, Ahmet and D'Huyvetter, Matthias and Xavier, Catarina and Van der Jeught, Kevin and Muyldermans, Serge and Van Der Heyden, José and Lahoutte, Tony and Tavernier, Jan and Devoogdt, Nick}},
  issn         = {{1535-7163}},
  journal      = {{MOLECULAR CANCER THERAPEUTICS}},
  keywords     = {{Y-90 IBRITUMOMAB TIUXETAN,B-CELL LYMPHOMA,PHASE-II TRIAL,FOLLICULAR LYMPHOMA,LOW-GRADE,MONOCLONAL-ANTIBODY,ANTI-HER2 NANOBODY,CHOP CHEMOTHERAPY,FOLLOW-UP,RITUXIMAB}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{2828--2839}},
  title        = {{Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma}},
  url          = {{http://dx.doi.org/10.1158/1535-7163.mct-17-0554}},
  volume       = {{16}},
  year         = {{2017}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: